key: cord-0924211-8sxalfo6 authors: Kinoshita, Masako; Sato, Kazuaki; Vellingiri, Balachandar; Green, Shawn J.; Tanaka, Masami title: Inverse association between hypertension treatment and COVID-19 prevalence in Japan date: 2021-06-03 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2021.05.071 sha: 0299c28f7ad4f7579389fa7e4a0c0dd0264faf7f doc_id: 924211 cord_uid: 8sxalfo6 OBJECTIVES: Cell entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) depends on angiotensin-converting enzyme II (ACE2). ACE2 is homologous with, but acts antagonistically to, angiotensin-converting enzyme (ACE), and has the critical function of protecting the lungs. ACE inhibitors are major antihypertensive agents. Thus, we aimed to analyze the impact of the prevalence of preexisting hypertension on the local spread of coronavirus disease 2019. METHODS: Data on SARS-CoV-2 infection and the estimated number of patients who received medical treatment based on disease classification using the International Statistical Classification of Diseases and Related Health Problems, 10th Revision, in each prefecture were obtained from the official Japanese notifications database. We analyzed the association between the proportion of patients with each disease and SARS-CoV-2-infection prevalence. RESULTS: The ratio of patients treated for diseases of the circulatory system, especially hypertensive disorders, per population demonstrated the most significant negative correlation with SARS-CoV-2-infection prevalence (Spearman’s rank correlation, p < 0.01). Age group analysis revealed a significant negative correlation in age groups 35–44, 45–54, 55–64, 75–84, and ≥85. CONCLUSIONS: Our findings suggest that hypertension treatment may play a protective role against the local spread of SARS-CoV-2 infection. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative virus for coronavirus disease 2019 . Cell entry of SARS-CoV-2 depends on angiotensin-converting enzyme II (ACE2), which is a membrane-associated zinc peptidase, and transmembrane serine protease 2 (TMPRSS2), J o u r n a l P r e -p r o o f which is a cellular serine protease (Zhou P et al., 2020; Hoffmann et al., 2020; Hirano and Murakami, 2020) . ACE2 is homologous with, but acts antagonistically to, angiotensin-converting enzyme (ACE), and has the critical function of protecting the lungs from severe acute injury (Imai et al., 2005) . The renin-angiotensin-aldosterone system is an essential regulator of blood pressure. Thus ACE inhibitors and angiotensin receptor blockers (ARBs) are commonly used as antihypertensive agents. Since both ACE inhibitors and ARBs increase ACE2 (Ferrario et al., 2005; Furuhashi et al., 2015) , the possibility of these drugs having either the unfavorable effect of promoting SARS-CoV-2 cell entry or the beneficial effect of preventing acute lung distress in patients with hypertension remains controversial (Schiffrin et al., 2020; Shibata et al., 2020) . Moreover, whether hypertension itself, as compared to other medical conditions, increases the risk of susceptibility to COVID-19 and severity thereof, or has an impact on local COVID-19 spread should be elucidated. In a previous study, we demonstrated that routine infant Bacillus Calmette-Guérin (BCG) vaccination coverage in the young generation had a significant impact on the prevention of local COVID-19 spread in Japan (Kinoshita and Tanaka, 2020) . In this study, we analyzed the effect of the proportion of local patients with preexisting hypertension and other medical conditions per population on the local prevalence of patients with COVID-19 infection, SARS-CoV-2 polymerase chain reaction-positive (PCR+) individuals, and COVID-19 deaths in Japanese prefectures. J o u r n a l P r e -p r o o f Prevalence of patients with Anonymous data on COVID-19 infection in Japan were obtained, as described in our previous study (Kinoshita and Tanaka, 2020) . In brief, the numbers of patients with COVID-19, SARS-CoV-2-PCR+ individuals, and COVID-19 deaths among Japanese residents in each prefecture were extracted from official notification records of the Ministry of Health, Labour and Welfare of Japan (Ministry of Health, Labour and Welfare of Japan, 2020). Data regarding their age and sex was not available. In Japan, COVID-19 diagnosis was made based on the Infectious Disease Surveillance System, in accord with the Act on the Prevention of Infectious Diseases and Medical Care for Patients with Infectious Diseases. Until March 29, 2020, the Act was applicable to individuals with symptoms suggestive of SARS-CoV-2 infection. Thereafter, the Act has also been applied to the asymptomatic population, and the official number of patients has also included PCR+ individuals presenting no clinical symptoms. In April 2020, the Japanese Prime Minister declared a state of emergency. Thus, in this study, data collected as of Table 1, Supplementary Tables 1A-1C ). The ratio of the estimated number of patients treated for each disease per day to the estimated number of individuals on October 1, 2019, in each prefecture was used as a surrogate for the local prevalence of patients with the disease. Though the number of patients per day, as estimated by the Patient Survey, was much smaller than the crude number of patients, the data were suitable for correlation analyses among prefectures or comparison among diseases. Data regarding the patients' age and sex were not available. As per the Kolmogorov-Smirnov test, variables did not exhibit a normal distribution. Therefore non-parametric Spearman's rank correlation coefficient was employed to evaluate the correlation of SARS-CoV-2 prevalence with each preexisting disease by using SPSS (version 16.0J; IBM Japan, Tokyo, Japan). The significance level was set at p=0.01. Prevalence data of patients with COVID-19, SARS-CoV-2-PCR+ individuals, and COVID-19 deaths in each prefecture have previously been reported (Kinoshita and Tanaka, 2020) . The 2017 Patient Survey demonstrated that circulatory system disease (Chapter Ⅸ, ICD-10) was the second-largest classification of the estimated number of patients nationwide (Table 1) . The prevalence of patients with COVID-19 on March 29 showed a significant negative correlation with the ratio of patients with diseases of the circulatory system, especially hypertensive disorders and cerebrovascular diseases that form its subcategory, and schizophrenia per population (p<0.01) ( Fig. 1, Table 1 ). Considering that our previous study demonstrated an inverse association between the elderly population and SARS-CoV-2-infection prevalence (Kinoshita and Tanaka, 2020) and suggested that the proportion of patients with hypertensive disorders increases with age, we further analyzed the correlation between SARS-CoV-2 infection and hypertension by age group. A significant negative correlation was shown between SARS-CoV-2-infection prevalence and the ratio of hypertension in age groups 35-44, 45-54, 55-64, 75-84 , and ≥85 ( Fig. 1 and Table 2 ). In this study, we analyzed the association of the ratio of local patients treated for preexisting hypertension and other medical conditions per population with SARS-CoV-2-infection prevalence in Japanese prefectures. The current study was the first to demonstrate that, among the diseases evaluated, diseases of the circulatory system, especially treated hypertension, exhibited the strongest inverse correlation with the local spread of SARS-CoV-2 infection in Japan. Moreover, statistical significance was still present after adjusting for the influence of age. Given prior reports indicating hypertension as a significant risk factor for COVID-19 incidence and severity (Zhou F et al., 2020; Wu et al., 2020) , a plausible explanation for this unexpected inverse relationship would be the potentially protective effect of antihypertensive medications. The relationship between hypertension and COVID-19 has been controversial (Schiffrin et al., 2020) . Initial studies in Wuhan, China, identified hypertension as the most common comorbidity in COVID-19 patients, especially those with lung injury (Zhou F et al., 2020; Wu et al., 2020) . After the discovery of the cell-entry mechanism of SARS-CoV-2 (Zhou P et al., 2020; Hoffmann et al., 2020; Hirano and Murakami, 2020) , the possibility of ACE inhibitors or ARBs having an unfavorable effect on COVID-19 secondary to the upregulation of ACE2 receptor sites theoretically facilitating viral cell entry has been a matter of great concern (Schiffrin et al., 2020; Shibata et al., 2020) . However, in contrast to this line of reasoning, ACE2 has known protective pulmonary and vascular functions. Furthermore, decreased ACE2 expression is associated with worse outcomes in other respiratory diseases via down regulation of the ACE2/angiotensin-(1-7)/Mas axis. In concordant with this hypothesis, recent clinical studies in COVID-19 patients with hypertension have shown no increased risk of harm (Hasan et al., 2020) ; and J o u r n a l P r e -p r o o f further demonstrated a favourable role of renin-angiotensin system inhibitors (Meng et al., 2020; Adrish et al., 2020; Baral et al., 2020; Matsuzawa et al., 2020; Şenkal et al., 2020) . A recent study revealed that ACE inhibitor use was associated with lower odds of COVID-19 among those aged ≥85 (An et al., 2021) . In our study, the type of hypertensive medication could not be evaluated. In Japan, calcium channel blockers are the most commonly used antihypertensives, and whereas ARBs are less often prescribed in hypertensive patients aged ≥75, they are almost equally used in patients younger than 75 years. In patients under 65 years, they narrowly become the most common antihypertensive medication class (Ishida et al., 2018) . With the prevalence of hypertension increasing with age and our previous study demonstrating an inverse association between ratios of the elderly population and SARS-CoV-2-infection prevalence (Kinoshita and Tanaka, 2020) , an additional analysis was performed to adjust for the influence of age, and statistical significance was present in younger age groups, even those in their thirties or forties. The current study demonstrated a significant inverse correlation between cerebrovascular disease and COVID-19. Hypertension is one of the most important risk factors for cerebral infarction and cerebral hemorrhage, and absolute risk reduction can be achieved through optimal blood pressure control (Kannel et al., 1981; Tanaka et al., 1982; Thomopoulos et al., 2014) . The use of ACE inhibitors or ARBs is recommended by the Japan Stroke Society considering the beneficial effects of improving insulin resistance, renal protection, and preventing atrial fibrillation (The Japan Stroke Society, 2019). Severe COVID-19 outcomes are associated with endothelial dysfunction (Varga et al., 2020) . ACE inhibitors and ARBs induce nitric oxide (NO) synthase, leading to the restoration of NO and improvement of endothelial dysfunction (Wagenaar et al., 2001; Palaniyappan et al., 2009 ). In addition, NO has direct antiviral activity in terms of preventing host-cell entry, virulence, or replication (Saura et al., 1999; Shulla et al., 2011; Green 1995 Green , 2020 . Host defense via NO can be activated by BCG inoculation in animal studies (Green et al., 1994) . This mechanism is possibly reinforced in Japan by the universal BCG vaccination policy. The abundant dietary nitrate content of traditional Japanese foods is a supply source of NO (Yamasaki 2020; Sobko et al., 2010) . In the present study, a significant inverse correlation was observed between schizophrenia and COVID-19. A recent study suggested the impact of a single nucleotide polymorphism (rs4702), located in the FURIN, on alveolar and neuron infection by SARS-CoV-2 in vitro (Dobrindt et al., 2020) . The downregulation of FURIN expression, which is specific to the rs4702 G allele, has been associated with abnormal migration neurodevelopment leading to schizophrenia (Fromer et al., 2016; Hou et al., 2018; Schrode et al., 2019) . The frequency of the rs4702 G allele in the Japanese population is relatively high (25.7%), whereas that in Yoruba Africans, the African ancestry in Southwest USA, or Luhya in Webuye, Kenya is negligible (SNPedia, 2020). Genetic preposition to SARS-CoV-2 infection warrants further studies. In summary, the current study demonstrated that the proportion of patients treated for preexisting hypertension was inversely associated with local COVID-19 spread in Japan. Analysis by age group showed that statistical significance was also present in patients in their thirties or forties. Antihypertensive J o u r n a l P r e -p r o o f Ethical approval for this study was waived because we used previously published data that did not contain any personal information. The association of renin-angiotensin-aldosterone system inhibitors with outcomes among a predominantly ethnic minority patient population hospitalized with COVID-19: the Bronx experience Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use and COVID-19 infection among 824 650 patients with hypertension from a US integrated healthcare system Effect of renin-angiotensin-aldosterone system inhibitors in patients with COVID-19: a systematic review and meta-analysis of 28,872 patients Common genetic variation in humans impacts in vitro susceptibility to SARS-CoV2 infection Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2 Gene expression elucidates functional impact of polygenic risk for schizophrenia Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker Nitric oxide: cytokine-regulation of nitric oxide in host resistance to intracellular pathogens Nitric oxide in mucosal immunity Covid-19 accelerates endothelial dysfunction and nitric oxide deficiency Mortality and disease severity among COVID-19 patients receiving renin-angiotensin system inhibitors: a systematic review and meta-analysis COVID-19: A new virus, but a familiar receptor and cytokine release syndrome SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Schizophrenia-associated rs4702 G allele-specific downregulation of FURIN expression by miR-338-3p reduces BDNF production Angiotensin-converting enzyme 2 protects from severe acute lung failure Current use of antihypertensive drugs in Japanese patients with hypertension: analysis by age group Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham study Impact of routine infant BCG vaccination on COVID-19 Renin-angiotensin system inhibitors and the severity of coronavirus disease Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension Comparison of vasopeptidase inhibitor omapatrilat and angiotensin receptor blocker candesartan on extracellular matrix, myeloperoxidase, cytokines, and ventricular remodeling during healing after reperfused myocardial infarction An antiviral mechanism of nitric oxide: inhibition of a viral protease Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19 Hypertension and COVID-19 Synergistic effects of common schizophrenia risk variants Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19 A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry Dietary nitrate in Japanese traditional foods lowers diastolic blood pressure in healthy volunteers Ministry of Internal Affairs and Communications of Japan. e-Stat Risk factors for cerebral hemorrhage and cerebral infarction in a Japanese rural community The influence of asymptomatic inflammatory prostatitis on the onset and progression of lower urinary tract symptoms in men with histologic benign prostatic hyperplasia Japanese Guidelines for the Management of Stroke Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials Endothelial cell infection and endotheliitis in COVID-19 Improvement of endothelial dysfunction in experimental heart failure by chronic RAAS-blockade: ACE-inhibition or AT1-receptor blockade? Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China Blood nitrate and nitrite modulating nitric oxide bioavailability: potential therapeutic functions in COVID-19 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study A pneumonia outbreak associated with a new coronavirus of probable bat origin We would like to thank Editage (www.editage.com) for English language editing.